$FBIO Balance Sheet | Understand Stock

$FBIO

$1.93 +$0.06 (3.21%) Close

$FBIO Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Balance Sheets

In millions of USD, except per-share amounts

	Q2 FY2026 As of Jun 30, 2026	Q1 FY2026 As of Mar 31, 2026	Q4 FY2025 As of Dec 31, 2025	Q3 FY2025 As of Sep 30, 2025	Q2 FY2025 As of Jun 30, 2025	Q1 FY2025 As of Mar 31, 2025	Q4 FY2024 As of Dec 31, 2024	Q3 FY2024 As of Sep 30, 2024	Q2 FY2024 As of Jun 30, 2024	Q1 FY2024 As of Mar 31, 2024	Q4 FY2023 As of Dec 31, 2023	Q3 FY2023 As of Sep 30, 2023	Q2 FY2023 As of Jun 30, 2023	Q1 FY2023 As of Mar 31, 2023	Q4 FY2022 As of Dec 31, 2022	Q3 FY2022 As of Sep 30, 2022	Q2 FY2022 As of Jun 30, 2022	Q1 FY2022 As of Mar 31, 2022	Q4 FY2021 As of Dec 31, 2021	Q3 FY2021 As of Sep 30, 2021
ASSETS
Current assets
Cash and cash equivalents
Accounts receivable, net
Inventory
Other receivables - related party
Other receivables
Prepaid expenses and other current assets
Restricted cash
Assets held for sale
Total current assets

Property, plant and equipment, net
Operating lease right-of-use asset, net
Restricted cash
Long-term investment, at fair value
Equity investments, at fair value
Intangible assets, net
Other assets
Total assets

LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)
Current liabilities
Accounts payable and accrued expenses
Accounts payable - related party
Deferred revenue
Income taxes payable
Common stock warrant liabilities
Operating lease liabilities, short-term
Partner company term loan, short-term, net
Partner company convertible preferred shares, short-term, net
Partner company line of credit
Partner company installment payments - licenses, short-term
Partner company notes payable, short-term
Other current liabilities
Total current liabilities

Notes payable, long-term
Operating lease liabilities, long-term
Partner company installment payments - licenses, long-term, net
Partner company convertible preferred shares, short-term (net of debt discount of $1,923 as of September 30, 2021 )
Partner company derivative warrant liabilities
Partner company redeemable perpetual preferred liability
Other long-term liabilities
Total liabilities
Stockholders' equity (deficit)
Cumulative redeemable perpetual preferred stock, $0.001 par value, 15,000,000 authorized, 5,000,000 designated Series A shares, 3,427,138 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively, liquidation value of $25.00 per share
Common stock, $0.001 par value, 200,000,000 shares authorized, 33,311,012 and 31,364,094 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively
Common stock issuable, 116,866 and 0 shares as of September 30, 2021 and December 31, 2020,respectively
Common stock issuable, 39,595 and 0 shares as of June 30, 2023 and December 31, 2022
Additional paid-in-capital
Accumulated deficit
Total stockholders' equity attributed to the Company
Non-controlling interests
Total stockholders' equity

Total liabilities and stockholders' equity

Comments